Related Experiment Video
Updated: Apr 27, 2026

Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites
Published on: March 16, 2018
Activity of melatonin against Leishmania infantum promastigotes by mitochondrial dependent pathway
Ehab Kotb Elmahallawy1, Aroa Jiménez-Aranda2, Antonio Sampedro Martínez3
1Department of Microbiology, Faculty of Medicine, University of Granada, Granada, Spain; Department of Zoonotic diseases, Faculty of Veterinary Medicine, Sohag University, Sohag, Egypt.
Abstract:
Visceral leishmaniasis, a potentially fatal disease, remains a major international health problem. Only a limited number of effective antileishmanial agents are available for chemotherapy, and many of them are expensive with severe side effects or have a markedly reduced effectiveness due to the development of drug resistance. Hence, there is a genuine need to develop a novel effective and less toxic antileishmanial drug. Melatonin, a neurohormone found in animals, plants, and microbes, can participate in various biological and physiological functions. Several in vitro or in vivo studies have reported the inhibitory effect of melatonin against many parasites via various mechanisms, including modulation of intracellular concentrations of calcium in the parasite and/or any other suggested mechanism. Importantly, many of available antileishmanial drugs have been reported to exert their effects by disrupting calcium homeostasis in the parasite. The objective of the present study was to test the efficacy of exogenous melatonin against Leishmania infantum promastigotes in vitro. Interestingly, melatonin not only demonstrated a significant antileishmanial activity of against promastigote viability in tested cultures but was also accompanied by an alteration of the calcium homeostasis of parasite mitochondrion, represented by earlier mitochondrial permeability transition pore opening, and by changes in some mitochondrial parameters are critical to parasite survival. These pioneering findings suggest that melatonin may be a candidate for the development of novel effective antileishmanial agents either alone or in associations with other drugs.
Insights
Melatonin shows significant anti-leishmanial activity against Leishmania infantum promastigotes by disrupting parasite mitochondrial calcium homeostasis. This suggests melatonin as a potential novel drug for treating visceral leishmaniasis.
Area of Science:
- Parasitology
- Pharmacology
- Biochemistry
Background:
- Visceral leishmaniasis is a serious global health issue with limited, often toxic, treatment options.
- Drug resistance and severe side effects necessitate new antileishmanial therapies.
- Melatonin, a neurohormone, exhibits antiparasitic effects through various mechanisms, including calcium modulation.
Purpose of the Study:
- To evaluate the in vitro efficacy of exogenous melatonin against Leishmania infantum promastigotes.
- To investigate the impact of melatonin on parasite calcium homeostasis, particularly in mitochondria.
Main Methods:
- In vitro culture of Leishmania infantum promastigotes.
- Assessment of parasite viability upon melatonin treatment.
- Analysis of mitochondrial calcium levels and permeability transition pore opening.
Main Results:
- Melatonin demonstrated significant antileishmanial activity, reducing promastigote viability.
- Melatonin treatment altered mitochondrial calcium homeostasis in the parasites.
- Earlier opening of the mitochondrial permeability transition pore was observed.
Conclusions:
- Melatonin exhibits potent in vitro efficacy against Leishmania infantum.
- Melatonin's mechanism involves disrupting parasite mitochondrial calcium homeostasis.
- Melatonin is a promising candidate for novel visceral leishmaniasis drug development, potentially in combination therapy.

